Zosano Pharma Corp. (NASDAQ: ZSAN) Attends 31st Annual ROTH Conference
Zosano Pharma (NASDAQ: ZSAN) is an emerging development company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy, but altering their delivery profile using the Company’s proprietary transdermal delivery system. Zosano Pharma has developed its proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications. Zosano Pharma’s investigational migraine treatment Qtrypta (M207) is being investigated as a potential treatment to provide rapid relief of migraine symptoms, at any time in the migraine cycle, in a discreet and simple manner. For more…







